Physician

Salaam Taha Alobeidy, MD

According to 2025 Medicare claims, Salaam Alobeidy, MD (NPI: 1760573513) practices pulmonary disease in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Atlantic, NJ. This provider's primary affiliated billing organization is AMERICAN SLEEP AND PULMONARY MEDICINE, PC (NPI: 1962682245; TIN: 26-0228169) and primary practice location at 08205-9438.

Alobeidy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 901 traditional Medicare patients, billed 8,044 HCPCS/CPT codes, and received $586,534 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,787 prescription claims across 669 beneficiaries totaling $4,436,372 in drug costs, led by Uptravi (Selexipag). DME data shows 6,329 claims. Open Payments data shows 88 records totaling $1,630. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,025,572 to $4,436,372. For DME billing, reported payments changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,049	9,606	$672,568
2016	1,188	9,108	$679,076
2017	1,013	8,062	$625,061
2018	1,057	8,266	$657,628
2019	988	7,521	$600,116
2020	801	5,044	$394,388
2021	853	5,632	$497,264
2022	862	5,696	$548,779
2023	913	6,699	$548,945
2024	901	8,044	$586,534

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	425	2,875	$1,025,572
2016	501	3,681	$1,779,338
2017	566	3,905	$2,535,849
2018	565	3,773	$2,260,623
2019	550	3,866	$2,463,251
2020	562	4,034	$3,547,092
2021	567	4,049	$4,010,251
2022	632	4,278	$4,047,659
2023	675	5,056	$4,856,616
2024	669	4,787	$4,436,372

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	2,060	6,786	$601,850
2016	2,236	7,728	$546,479
2017	1,977	6,624	$487,158
2018	1,652	5,553	$415,723
2019	1,569	4,766	$350,786
2020	1,613	5,528	$467,562
2021	1,624	5,558	$511,709
2022	1,569	4,650	$419,150
2023	1,822	5,608	$503,642
2024	2,068	6,329	$453,521

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	628	1,801	$143
94729	Test to examine how well the lungs exchange gases	460	725	$47
94726	Test to determine lung volumes using sensors	458	726	$46
94618	Test for exercise-induced lung stress	326	430	$28
94010	Test to measure expiratory airflow and volume	493	848	$23

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Uptravi	Selexipag	37	1,087	$845,295
Opsumit	Macitentan	57	1,687	$714,703
Ofev	Nintedanib Esylate	49	1,470	$602,142
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	606	22,380	$461,662
Adempas	Riociguat	29	808	$373,401

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	33	152	$118,718
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	66	$67,153
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	79	632	$44,080
A7030	Full face mask used with positive airway pressure device, each	N	127	292	$23,190
A7031	Face mask interface, replacement for full face mask, each	N	107	266	$20,337

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	88	$1,630	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Salaam Taha Alobeidy, MD?

Tedicare shows public-source Medicare data for Salaam Taha Alobeidy, MD (NPI 1760573513), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Salaam Taha Alobeidy, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Salaam Taha Alobeidy, MD?

Salaam Taha Alobeidy, MD is linked to AMERICAN SLEEP AND PULMONARY MEDICINE, PC (billing NPI 1962682245) in the available physician profile data.

Does Salaam Taha Alobeidy, MD have Open Payments data?

Salaam Taha Alobeidy, MD has 88 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.